Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC

J Thorac Oncol. 2021 Dec;16(12):1994-1998. doi: 10.1016/j.jtho.2021.07.033.

¹ Department of Medicine, University of California, San Francisco, California.
² Division of Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
³ Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
⁴ Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California. Electronic address: hwakelee@stanford.edu.

No abstract available

Publication types